From Principle to Practice: New Checklist Supports Patient Engagement in Rare Disease Value Research

Why It Matters

Formalizing patient engagement strengthens the relevance and credibility of health‑technology assessments, guiding payers and regulators toward decisions that truly reflect rare‑disease patient priorities. This can narrow evidence gaps and accelerate access to effective therapies.

Key Takeaways

• New RDPE checklist standardizes patient engagement in rare disease research
• Toolkit includes guidance, PDF checklist, and visual executive summary
• Developed with EveryLife, NORD; funded by PCORI, Alexion, AstraZeneca
• Aims to align outcomes with patient priorities, close evidence gaps
• Researchers encouraged to share implementation examples for iterative refinement

Pulse Analysis

Rare‑disease research has historically suffered from a disconnect between clinical endpoints and the lived experiences of patients and families. Traditional health‑technology assessments often rely on limited data sets, leaving critical quality‑of‑life outcomes under‑represented. As regulatory bodies and payers demand more patient‑centric evidence, the industry faces pressure to integrate authentic patient voices throughout the research lifecycle. This shift underscores the need for structured tools that can translate patient insights into measurable, actionable criteria.

The RDPE Guidance and Checklist answers that need by offering a three‑part package: concise best‑practice guidance, a downloadable PDF checklist for real‑time documentation, and a visual executive summary that distills the framework for quick reference. Designed for researchers, advocacy groups, payers, and policy stakeholders, the checklist maps engagement activities to each phase of comparative effectiveness research, value assessment, and economic modeling. By prompting users to identify evidence gaps, prioritize outcomes that matter to patients, and document interactions transparently, the toolkit fosters reproducible, credible HTA outputs.

Beyond improving study design, the checklist has broader market implications. Payers can rely on more patient‑aligned evidence when negotiating coverage, while manufacturers gain clearer pathways to demonstrate value in rare‑disease indications. The call for shared implementation examples creates a feedback loop that can refine the methodology, driving industry standards toward greater inclusivity. As the rare‑disease ecosystem embraces this patient‑centered approach, stakeholders can expect faster decision‑making, reduced uncertainty, and ultimately, better access to therapies for underserved populations.